Molecular Engines Laboratories Gains Exclusive Access to Ingenium's INGENOtypes(R) Mouse Model for Cancer Gene
2003年10月28日 - 5:00PM
PRニュース・ワイアー (英語)
Molecular Engines Laboratories Gains Exclusive Access to Ingenium's
INGENOtypes(R) Mouse Model for Cancer Gene -- Model Represents
Novel Opportunity to Understand Function of TSAP6 Gene -- PARIS,
and MUNICH, Oct. 28 /PRNewswire/ -- Ingenium Pharmaceuticals AG and
Molecular Engines Laboratories (MEL) announced today an agreement
under which MEL gains exclusive rights to Ingenium's INGENOtypes(R)
TSAP6 genetic mouse model. TSAP6 is a gene discovered by MEL's
scientific founders to have a role in cancer tumor reversion.
Ingenium discovered the TSAP6 mouse model through its Deductive
Genomics(R) approach, which screens animals with random alterations
in the genome. The model was selected from the screen due to its
specific phenotype. Terms of the agreement were not disclosed.
"Ingenium's expertise in rodent genetics allows us to offer
completely novel disease models that are extremely valuable for
functional genomics research and for target validation and compound
profiling," said Michael C. Nehls, M.D., Ph.D., Chief Executive
Officer of Ingenium. "As demonstrated for the first time with this
agreement, Ingenium has the ability to provide these models on an
exclusive license basis, which represents a significant advantage
for companies such as Molecular Engines, who are establishing their
leadership position in a particular therapeutic area." "Molecular
Engines is further validating its specific approach to cancer,
namely by working on genes that play a role in the cellular
reprogramming process leading to suppression of tumorigenicity,"
stated Pierre Attali, CEO of the company. "We believe that TSAP6 is
one of these genes and therefore are very pleased to have complete
access to this INGENOtypes(R) model which we anticipate to play a
crucial role in our further target validation studies," said Robert
Amson and Adam Telerman, founders and CSOs of MEL. About the
INGENOtypes(R) platform Ingenium has developed and biologically
characterized multiple proprietary mouse models of human disease
called INGENOtypes(R). These models represent an important tool in
biomedical research for drug target validation and for testing
therapeutic hypotheses and drug compounds. Ingenium derives its
unique models from its proprietary Deductive Genomics(R) and
INGENOtyping(TM) platforms. INGENOtypes(R) are either completely
novel models of human disease or display modifications of known
genes where models have previously not been broadly available. The
basis of Ingenium's business is its knowledge and expertise in
generating the biological information critical to the discovery,
validation and development of therapeutics. Ingenium's Deductive
Genomics(R) technology combines genome-covering mutagenesis in the
murine model system with a proprietary, therapeutic goal-oriented
biological screen. From the breadth of knowledge generated by
Deductive Genomics(R), Ingenium is currently advancing a pipeline
of novel models and biologically validated drug targets in the
areas of inflammatory bowel disease, diabetes/obesity, and
neurological disorders. The company's INGENOtyping(TM) platform
offers an alternative to producing genetically-altered murine
models. Ingenium has research partnership agreements with Elan
Corporation, Bayer AG, F. Hoffmann-La Roche Ltd., Sequenom Inc.,
Oxagen Limited and Lynkeus BioTech GmbH, in addition to numerous
international academic collaborations. Molecular Engines
Laboratories (MEL) is a private biotechnology company whose purpose
is to develop novel therapeutics for cancer. MEL's strategy, as
conceived by Drs. Adam Telerman and Robert Amson, is to
characterize most of the genes associated with tumor reversion and
to understand their mechanism of action in order to induce the
reversion of malignant cells to suppressed- phenotype cells. MEL is
currently completing a drug discovery program on its first target,
based on tumour reversion process. Ingenium, INGENOtypes and
Deductive Genomics are registered U.S. trademarks. DATASOURCE:
Ingenium Pharmaceuticals AG CONTACT: Gretchen L.P. Schweitzer, Vice
President, Ingenium Pharmaceuticals AG, 49 89 8565 2398, ; or
Pierre Attali, Chief Executive Officer of Molecular Engines
Laboratories, 33 1 44 64 04 64, Web site:
http://www.ingenium-pharmaceuticals.com/
Copyright